Continuous glucose monitoring for people with type 2 diabetes on insulin after hospital discharge
Compares continuous glucose sensors with finger-prick testing in insulin-treated adults leaving hospital.
Plain-language title generated from the registry record
Registry title: CGM for Insulin-Treated T2DM During Post-Discharge Transition
Key facts
- Where
- Shanghai, ChinaSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07414277, who can take part
Where in China
- Shanghai 6th People's HospitalShanghai, ChinaTaking people
- Shanghai 7th People's HospitalShanghai, ChinaTaking people
- Shanghai Fengxian District Central HospitalShanghai, ChinaTaking people
- Shanghai General HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai 6th People's Hospital
- Trial code
- NCT07414277
- Record updated
- 24 June 2026
- Original description
The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period.Read full original descriptionShow less
Effects of Continuous Glucose Monitoring on Patients With Type 2 Diabetes Treated With Insulin During Post-Discharge Transition: A Multicenter Randomized Controlled Trial
The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period.
A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.
Inclusion: Age 18 to 80 years (inclusive); Confirmed diagnosis of type 2 diabetes mellitus (T2DM); HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment; Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician).
Exclusion: Current use of oral corticosteroid therapy, or anticipated use during the trial period; Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives; Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders; Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment; Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN); Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²; Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period; Currently participating in, or planning to participate in, another clinical trial.